NETRF is pleased to share these job opportunities within the NET research community. Click on any job listing below to view details.
POSTDOCTORAL RESEARCH ASSOCIATE, TRANSLATIONAL CANCER BIOLOGY, TNS (MULTIPLE)(PHOENIX)
The laboratory of Dr. James Bibb at the Department of Translational Neurosciences is looking for an enthusiastic and motivated Postdoctoral Research Associate to work on research projects aimed at delineating the causes and developing new treatments for cancers including neuroendocrine cancer. The research involves investigating signal transduction and metabolic alterations in neuroendocrine cancers using cutting-edge technologies, and multi-omics platforms. Multidisciplinary approaches include the generation of novel animal models, studies with human tumor tissue, and cell-based models, as well as metabolism, mitochondrial dynamics, phosphoproteomics, single cell multiomics, biomarker diagnostics, and drug discovery and testing. Successful candidates will join a multidisciplinary team within the setting of an outstanding new facility with capabilities in imaging, flow cytometry, bioinformatics, high throughput screening, phosphoproteomics, and other advanced approaches. The position is part of a well-funded research program and will provide the opportunity to produce high-impact publications and establish a record of grant award funding. The candidate will be mentored in career development toward independent research and training to become a principal investigator. Opportunities to expand to other cancer types and other systems will be provided. Enthusiastic applicants with strong expertise in molecular or cellular biology, biochemistry, pharmacology, multi-omic analyses, metabolism, animal models, and drug testing are encouraged to apply.
The mission of the Translational Neurosciences Department is to leverage innovative and advanced research approaches to discover the causes of neurological and mental health disorders and translate those insights into new therapies. The Department occupies a brand new 9,000 square foot, $15 million, state of the art research space with many advanced capabilities, and is linked to a newly constructed and well-designed animal research facility. Our goal is to establish national and international impact in basic, translational, and preclinical neuroscience research.
This position is eligible for visa sponsorship.
A postdoctoral research position is available starting January 1, 2023, in the laboratory of Dr. Dawn Quelle. The lab investigates druggable mechanisms driving neuroendocrine tumor and sarcoma pathogenesis with the goal of developing more effective therapies for patients with those cancers. This NIH R01 funded position seeks to define the role of RABL6A-PP2A signaling in neuroendocrine tumor progression, metastasis and response to targeted therapy. Studies include analyses of human tumor specimens for pathway alterations as well as molecular and cell biological analyses in cancer derived cells testing how each factor affects cell biology and drug responsiveness. In vivo studies employ novel genetic knockout/transgenic mice and xenograft mouse models enabling bioluminescence imaging of tumors. The lab is tightly affiliated with the University of Iowa’s NCI designated Holden Comprehensive Cancer Center, uses exceptional core research facilities, and collaborates extensively with clinical colleagues in surgical oncology, genetics, medical oncology, imaging and pathology.
Requirements: A motivated individual with a Ph.D. in biomedical sciences is required. Practical experience with mammalian cell culture, molecular biology, analyses of cell signaling pathways, tumor immunology and/or drug response studies is highly desired. Must be willing to work with mice, prior experience is preferred.
The University of Iowa is located in Iowa City, Iowa, a fun, safe, mid-sized college town in the Midwest of the United States with high living standards and an inexpensive cost of living relative to larger cities.
You would be joining a vibrant community of postdoctoral scholars at the University of Iowa who are a vital part of our research innovation and success. The Graduate College provides a wide range of resources that will help you thrive in your research efforts and further develop your professional skills. The following site details those resources, including salary and outstanding benefits, that support your training success and personal happiness at Iowa.
https://grad.uiowa.edu/postdoctoral-affairs
To apply, please send curriculum vitae, statement of previous research experience and current research interests, and the names and contact information for three references to:
Dr. Dawn E. Quelle
Department of Neuroscience and Pharmacology
Phone: 319-353-5749
Email: dawn-quelle@uiowa.edu
https://medicine.uiowa.edu/neuroscience-and-pharmacology/profile/dawn-quelle
The University of Iowa is an equal opportunity/affirmative action employer. All qualified applicants are encouraged to apply and will receive consideration for employment free from discrimination on the basis of race, creed, color, religion, national origin, age, sex, pregnancy (including childbirth and related conditions), disability, genetic information, status as a U.S. veteran, service in the U.S. military, sexual orientation, gender identity, or associational preferences.
The laboratory of Dr James Bibb at the Department of Translational Neurosciences is looking for an enthusiastic and motivated Postdoctoral Research Associate to work on research projects aimed at delineating the causes and developing new treatments for cancers including neuroendocrine cancer. The research involves investigating signal transduction and metabolic alterations in neuroendocrine cancers using cutting-edge technologies, and multi-omics platforms. Multidisciplinary approaches include the generation of novel animal models, studies with human tumor tissue, and cell-based models, as well as metabolism, mitochondrial dynamics, phosphoproteomics, single cell multiomics, biomarker diagnostics, and drug discovery and testing. Successful candidates will join a multidisciplinary team within the setting of an outstanding new facility with capabilities in imaging, flow cytometry, bioinformatics, high throughput screening, phosphoproteomics, and other advanced approaches. The position is part of a well-funded research program and will provide the opportunity to produce high-impact publications and establish a record of grant award funding. The candidate will be mentored in career development toward independent research and training to become a principal investigator. Opportunities to expand to other cancer types and other systems will be provided. Enthusiastic applicants with strong expertise in molecular or cellular biology, biochemistry, pharmacology, multi-omic analyses, metabolism, animal models, and drug testing are encouraged to apply. Outstanding UA benefits include health, dental, vision, and life insurance; paid vacation, sick leave, and holidays; UA/ASU/NAU tuition reduction for the employee and qualified family members; access to UA recreation and cultural activities; and more! | |
| Duties & Responsibilities |
Knowledge, Skills, and Abilities:
|
| Minimum Qualifications |
|
| Preferred Qualifications | ● Established expertise in molecular biology, intracellular signal transduction, cell culture techniques, vector design, stable transfection, protein biochemistry, confocal microscopy & live cell imaging. ● Experience in working with animal models of cancer, imaging techniques to monitor tumor growth and cancer progression, drug testing. ● Experience in multi-omics approaches, including sc-RNA-seq, bulk RNAseq, phosphoproteomics and bioinformatics. ● Experience publishing papers in peer reviewed journals. |
Location: CCSR 2255-A, 1291 Welch Rd., Stanford, CA 94305-5165
Project: Advancing a mouse model of SDHB hereditary pheochromocytoma and paraganglioma (hPPGL).
Brief Summary: The goals of this project are (1) to understand the molecular mechanism of SDHB-deficient PPGL tumorigenesis and (2) to develop therapeutic leads for the treatment of SDHx tumors. This work will leverage the recently generated SDHB PPGL mouse model that has been generated in the lab and the laboratory’s expertise in chemical screening and drug development. The project is supported by a full-time medicinal chemist to enable novel therapeutic development. Competitive post-doctoral candidates should be highly motivated, interested/experienced in animal disease models and interested in therapeutic identification/development.
Position availability: Immediately
Contact: Justin Annes MD PhD (jannes@stanford.edu)
The goals of this project are (1) to understand the molecular mechanism of SDHB-deficient PPGL tumorigenesis and (2) to develop therapeutic leads for the treatment of SDHx tumors. This work will leverage the recently generated SDHB PPGL mouse model that has been generated in the lab and the laboratory’s expertise in chemical screening and drug development.
We have open positions in the lab for postdoctoral fellows who are interested in working on spatial and systems oncology applied to GI malignancies, with a particular focus on pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors. The Hwang lab is focused on studying tumor-stroma interactions at unprecedented resolution through the development and application of techniques in single-cell and spatial biology, multiplexed imaging, and functional genetic screens to patient-derived specimens, organoids, and mouse models to elucidate mechanisms of (1) therapeutic resistance mediated by genetic, epigenetic, and phenotypic factors including cell state plasticity; (2) treatment-mediated remodeling of the spatial microarchitecture of tumors and underlying cancer cell-stromal interactions; and (3) tumor-nerve crosstalk, which plays a critical role in the pathophysiology and morbidity of many malignancies but remains understudied.
Contact: William Hwang, MD, PhD (whwang1@mgh.harvard.edu)
We have open positions in the lab for postdoctoral fellows who are interested in working on spatial and systems oncology applied to GI malignancies, with a particular focus on pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors.
Lautenberg Center for Immunology and Cancer Research, Hebrew University Hadassah Medical School, Jerusalem, Israel
Our lab combines cutting edge experimental techniques with big-data analytical approaches to study how genetic and epigenetic alterations of regulatory DNA elements drive cancer. We are recruiting post-doctoral researchers and PhD students that will either focus mostly on the experiential and biological aspects, the computational analysis, or wish to combine both. We focus on two types of regulatory DNA elements: enhancers (regulating transcription), and CTCF binding sites (regulating chromosomal topology, i.e. the folding of the chromosome in 3D).
Intratumoral and intertumoral regulatory heterogeneity
We develop systematic approaches to integrate genetic, epigenetic, topologic and transcriptional information to study how epigenetic alterations affect cis regulatory DNA elements, and their variation between tumors and between the different cancer cells within each tumor. For example,
we have recently uncovered different regulatory and developmental subtypes of pancreatic neuroendocrine tumors [1], and paracrine interactions between different cell types that constitute adenoid cystic carcinomas [2]. We are now extending these efforts to study lung neuroendocrine tumors and hepatocellular carcinomas.
Tumorigenic epigenetic topological alterations
We have previously demonstrated that aberrant DNA methylation of CTCF binding sites in IDH-mutant glioma [1] and SDH deficient gastrointestinal stromal tumors [2] perturbs chromosomal topology. In these tumors, accumulation of DNA methylation at the boundary between two topological domains inhibits CTCF binding and disrupts the insulation between the domains. This leads to aberrant interactions between an oncogene in one domain and enhancers in the other, leading to over-expression of the oncogene. This groundbreaking model links metabolic, epigenetic and topological alterations and demonstrates how they can drive cancer. We are now extending this framework to additional types of cancer including SDH deficient pheochromocytoma and IDH mutant cholangiocarcinoma to study the basic principles of epigenetic topologic alterations, and to uncover drivers and sensitivities of pheochromocytoma and cholangiocarcinoma.\
Position start date is flexible.
Laboratory: The Drier Lab for Systems Biology of Cancer, http://yotamdrier.ekmd.huji.ac.il/
To apply send your CV and a short application letter to yotam.drier@mail.huji.ac.il
References:
[1] Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Cejas P,* Drier Y*, et al. Nature Medicine, 2019.
[2] Single cell RNA-sequencing identifies a paracrine interaction that may drive oncogenic Notch signaling in human adenoid cystic carcinoma. Parikh*, Wizel* et al. Cell Reports, in print.
[3] Insulator dysfunction and oncogene activation in IDH mutant gliomas. Flavahan WA*, Drier Y*, et al. Nature, 2016.
[4] Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST. Flavahan WA*, Drier Y*, et al. Nature 2019, 575(7781), 229–233.
Our lab combines cutting edge experimental techniques with big-data analytical approaches to study how genetic and epigenetic alterations of regulatory DNA elements drive cancer. We are recruiting post-doctoral researchers and PhD students that will either focus mostly on the experiential and biological aspects, the computational analysis, or wish to combine both.
The Dayton lab at EMBL Barcelona is recruiting postdoctoral researchers interested in dissecting the mechanisms of tumor initiation and progression in pulmonary neuroendocrine cancers.
The Dayton lab develops 3D in vitro organoid models of human tissue to recapitulate developmental and cancer phenotypes of pulmonary neuroendocrine cells. The group has two broad areas of interest – development and cancer – and we want to understand how these intersect and can be manipulated for patient benefit.
We also develop patient derived tumor organoid models of pulmonary neuroendocrine tumors and of large cell neuroendocrine carcinoma, for mechanistic studies aimed at understanding tumor progression, tumor evolution, and drug response. More information about the lab can be found on their website: https://www.embl.org/groups/dayton/.
Dr. Dayton aims to create an inclusive & fun team environment where team members support and inspire each other so that they can solve problems and address important questions together. Dr. Dayton is committed to supporting the career development of her team members.
Interested candidates can submit a cover letter and their CV to Talya Dayton, PhD (talya.dayton@embl.es)
The Dayton lab at EMBL Barcelona is recruiting postdoctoral researchers interested in dissecting the mechanisms of tumor initiation and progression in pulmonary neuroendocrine cancers.